Azienda Sanitaria Locale TO4
- Address
- Piazza Credenza 2, 10015 Ivrea, Italy
Hematology and Lymphatic Diseases
At Azienda Sanitaria Locale TO4 in Ivrea, research in Hemic and Lymphatic Diseases focuses on follicular lymphoma, with studies designed to improve maintenance treatment and long-term disease control after initial therapy.
- Evaluating whether a new maintenance approach can extend progression-free survival in relapsed or refractory follicular lymphoma
- Comparing treatment strategies to better manage lymphoma after chemoimmunotherapy
- Supporting care decisions for patients not eligible for transplant-based options
This work centers on testing treatment effectiveness and refining follow-up care for patients with blood and lymphatic cancers.
Cardiovascular Diseases
Clinical research in Cardiovascular Diseases includes studies on pulmonary arterial hypertension and transthyretin amyloid cardiomyopathy, aiming to improve outcomes in serious heart and circulation disorders.
- Assessing a new therapy for people with pulmonary arterial hypertension alongside standard care
- Studying safety and tolerability while exploring symptom and disease control
- Testing whether treatment can reduce cardiovascular death and illness in amyloid-related heart failure
These trials focus on evaluating novel treatments and measuring their impact on major cardiovascular events and patient well-being.
Respiratory Tract Diseases
The site also contributes to research in Respiratory Tract Diseases, with overlap in studies of pulmonary arterial hypertension, a condition that affects the lungs and the heart.
- Exploring whether an investigational therapy can improve disease control in patients with functional limitation
- Tracking safety and tolerability in participants receiving treatment with standard care
- Helping define better options for a complex cardiopulmonary disorder
Overall, the research aims to test new therapies and strengthen treatment options for patients with challenging respiratory-related vascular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novartis Pharma AG1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale TO4
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM). | Novo Nordisk A/S | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ltp001 | 1 | Unknown | 2025-09-18 | 2025-09-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.